Medifast (MED)
NYSE:MED
Want to see MED full AI Analyst Report?
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$9.22 - $15.46
Previous CloseN/A
Volume160.90K
Average Volume (3M)191.80K
Market Cap
$139.32M
Enterprise Value$83.89M
Total Cash (Recent Filing)$168.95M
Total Debt (Recent Filing)$16.10M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 10, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding11,119,115
10 Day Avg. Volume183,984
30 Day Avg. Volume191,800
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit0.35
Enterprise Value/Ebitda45.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$273.70M
Bulls Say, Bears Say
Bulls Say
Balance Sheet & LiquidityA large cash position and negligible debt provide multi-quarter runway to execute restructuring, fund the planned product launch, and absorb near-term losses without urgent refinancing. This financial flexibility supports durable execution of cost-savings and go-to-market initiatives.
Coach Productivity ImprovementSustained increases in revenue per active coach improve unit economics of the direct-sales model and can offset lower coach counts. If productivity gains persist, the company can stabilize revenue and margins through higher yield per channel participant rather than relying solely on recruiting.
Clinical Differentiation & PipelineA differentiated metabolic-health product backed by clinical results (visceral fat reduction, lean mass preservation) can strengthen competitive positioning versus GLP-1 disruption. A successful proprietary system would increase stickiness, justify coach recommendations, and improve long-term margins.
Bears Say
Revenue & Profitability DeclineA steep multi-quarter revenue decline and recent negative margins signal structural demand weakness. Sustained top-line deterioration limits operating leverage, compresses profitability, and reduces the firm's ability to finance growth or reinvest, making recovery dependent on durable product and channel improvements.
Erosion Of Primary DistributionThe coach network is the company's primary acquisition and retention engine. A nearly 45% decline in active earning coaches represents a structural hit to recurring revenue, referral flows, and community-driven growth. Rebuilding that channel is time-consuming and central to long-term revenue normalization.
Weakening Cash Generation / FCFNegative trailing free cash flow erodes internal funding for marketing, product development, and inventory investment. Even with healthy liquidity today, sustained weak cash conversion would constrain strategic options, increase reliance on cost cuts, and raise the stakes on execution of the turnaround roadmap.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $9.22 and its highest was $15.46 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $139.32M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is Aug 10, 2026 which is in 69 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on May 04, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.33.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Overvalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.65.
How many shares outstanding does Medifast have?
Medifast has 11,119,115 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 22.484%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MED Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $241.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.44%
12-Months-Change
Fundamentals
Return on Equity
-9.68%
Trailing 12-Months
Asset Growth
-9.99%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear early operational and scientific progress — notably improving coach productivity, sequential revenue stabilization, a strong cash position, cost-savings initiatives, and a defined metabolic-health product roadmap — against substantial near-term financial headwinds, including a 34% YoY revenue decline, a roughly 45% drop in active earning coaches, compressed gross margins, and continued net losses. Management is optimistic about trajectory and expects profitability improvements beginning in Q4 2026 contingent on execution and the new product rollout, but material risks remain.View all MED earnings summariesTechnical Analysis
Ownership Overview
5.98% Insiders
14.57% Mutual Funds
14.40% Other Institutional Investors
45.79% Public Companies and
Individual Investors